Practical recommendations and new therapies for Wilson's disease
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Wilson's disease is an inherited disorder of copper accumulation. The basic defect is a failure of excretion of excess copper in the bile by the liver for loss in the stool. The accumulating copper causes damage primarily to the liver and the brain. Patients typically present in the second to the fourth decades of life with liver disease, a neurological disease of the movement disorder type, or a wide array of behavioural disturbances. Because the manifestations of Wilson's disease are so protean, and the disease masquerades so well as something else, recognition of the possibility of Wilson's disease is a major problem, leading to serious underdiagnosis of the disease. Excellent therapies exist for both the prophylaxis and treatment of Wilson's disease. The longer recognition and diagnosis are delayed, the greater the risk of permanent damage to liver and/or brain. The availability of effective therapy and the risks in delay or therapy make the earliest possible diagnosis critical. Once the disease comes under consideration, a series of diagnostic steps can be undertaken which almost always establish or rule out the diagnosis of Wilson's disease. These include urine copper, blood ceruloplasmin, slit lamp examination for Kayser-Fleischer rings, and liver biopsy with quantitative copper assay. Currently, there are 4 drugs being used as anticopper agents in Wilson's disease. These are zinc, which blocks intestinal absorption of copper, penicillamine and trientine, both of which are chelators that increase urinary excretion of copper, and tetrathiomolybdate which forms a tripartite complex with copper and protein, and can block copper absorption from the intestine, or render blood copper non-toxic. Zinc is clearly the treatment of choice, in our opinion, for maintenance therapy, for the treatment of the presymptomatic patient from the beginning and for the treatment of the pregnant patient, because of its complete efficacy and lack of toxicity. For the initial treatment of the patient presenting with mild liver failure, we empirically use a combination of trientine and zinc. Trientine gives a strong, fast, negative copper balance, and zinc induces hepatic metallothionein, which sequesters hepatic copper. For the initial treatment of patients presenting with neurological disease we use an experimental drug, tetrathiomolybdate, which provides rapid, safe control of copper. These latter patients are at great risk of serious permanent neurological worsening with penicillamine, and zinc is too slow-acting, in our judgment, to be optimal.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Wilson's disease is an inherited autosomal disorder of copper accumulation. The excretion of liver copper in the bile is decreased. This leads to failure of proper copper excretion in the stool and to the accumulation of copper in the liver. Eventually not only the liver but also brain and other organs are damaged due to excess copper accumulation.”
From Discovery of Human Zinc Deficiency: Its Impact on Human Health and Disease (2013) · cites this paper as [66]
In the citing paper
“Patients typically present with liver disease, neurological disease (movement disorder), or psychiatric disturbances in the second to fourth decades of life. In many cases, the diagnosis is either missed or delayed (65, 66).”
From Discovery of Human Zinc Deficiency: Its Impact on Human Health and Disease (2013) · cites this paper as [66]
In the citing paper
“For maintenance therapy, zinc is the drug of choice (65, 66).”
From Discovery of Human Zinc Deficiency: Its Impact on Human Health and Disease (2013) · cites this paper as [66]
In the citing paper
“This led Brewer et al. (65, 66) to develop zinc as an effective anticopper drug for Wilson's disease.”
From Discovery of Human Zinc Deficiency: Its Impact on Human Health and Disease (2013) · cites this paper as [66]
In the citing paper
“Measurement of the 24-h urinary copper is a good diagnostic test because this is consistently elevated in these patients (65, 66).”
From Discovery of Human Zinc Deficiency: Its Impact on Human Health and Disease (2013) · cites this paper as [66]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Metabolic Basis of Inherited Disease.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-503_7 · Cited by 7,786
The Wilson disease gene is a putative copper transporting P–type ATPase similar to the Menkes gene
Bull, P. C., Thomas, G. R., Rommens, J. M., Forbes, J. R., & Cox, D. W. (1993) · Nature Genetics · doi:10.1038/ng1293-327 · Cited by 1,948
The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene
Tanzi, R. E., Petrukhin, K., Chernov, I., Pellequer, J. L., Wasco, W., Ross, B., Romano, D. M., Parano, E., Pavone, L., Brzustowicz, L. M., et al. (1993) · Nature Genetics · doi:10.1038/ng1293-344 · Cited by 1,375
Penicillamine, a new oral therapy for Wilson's disease
Walshe, J. M. (1956) · The American Journal of Medicine · doi:10.1016/0002-9343(56)90066-3 · Cited by 707
Isolation and Characterization of a Human Liver cDNA as a Candidate Gene for Wilson Disease
Yamaguchi, Y., Heiny, M. E., & Gitlin, J. D. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.2471 · Cited by 509
TREATMENT OF WILSON'S DISEASE WITH TRIENTINE (TRIETHYLENE TETRAMINE) DIHYDROCHLORIDE
Walshe, J. M. (1982) · The Lancet · doi:10.1016/s0140-6736(82)92201-2 · Cited by 378
Brewer, G. J., Terry, C. A., Aisen, A. M., & Hill, G. M. (1987) · Archives of Neurology · doi:10.1001/archneur.1987.00520170020016 · Cited by 335
Self-citationBREWER, G. J., & YUZBASIYAN-GURKAN, V. (1992) · Medicine · doi:10.1097/00005792-199205000-00004 · Cited by 303
Self-citationMajor Problems in Internal Medicine
MacLennan, I. C. M. (1978) · Journal of Clinical Pathology · doi:10.1136/jcp.31.12.1255-c · Cited by 287
Copper Metabolism in Normal Subjects
CARTWRIGHT, G. E., & WINTROBE, M. M. (1964) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/14.4.224 · Cited by 265
Cited by
Discovery of Human Zinc Deficiency: Its Impact on Human Health and Disease
Prasad, A. S. (2013) · Advances in Nutrition · doi:10.3945/an.112.003210 · Cited by 919
“For maintenance therapy, zinc is the drug of choice (65,66).”
BackgroundInfluentialClinical presentation, diagnosis and long-term outcome of Wilson’s disease: a cohort study
Merle, U., Schaefer, M., Ferenci, P., & Stremmel, W. (2007) · Gut · doi:10.1136/gut.2005.087262 · Cited by 625
Copper and Zinc, Biological Role and Significance of Copper/Zinc Imbalance
Osredkar, J. (2011) · Journal of Clinical Toxicology · doi:10.4172/2161-0495.s3-001 · Cited by 620
“The treatment of Wilson’s disease involves avoidance of foods rich in copper and any supplements containing copper and drug treatment with chelating agents that remove the excess copper from the body (D-penicillamine, Zn acetate)[153].”
BackgroundBao, B., Prasad, A. S., Beck, F. W., Fitzgerald, J. T., Snell, D., Bao, G. W., Singh, T., & Cardozo, L. J. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28836 · Cited by 400
“50 mg zinc/d for 12 wk may induce copper deficiency (11, 12).”
Zinc as an essential micronutrient: A review
Salgueiro, M. J., Zubillaga, M., Lysionek, A., Sarabia, M. I., Caro, R., De Paoli, T., Hager, A., Weill, R., & Boccio, J. (2000) · Nutrition Research · doi:10.1016/s0271-5317(00)00163-9 · Cited by 370
Metadata
- Authors
- Brewer, G. J.
- Affiliations
- University of Michigan (US)
- Corresponding author
- Brewer, George J.
- Venue
- Drugs
- Published
- 1995-08
- Volume
- 50
- Issue
- 2
- Pages
- 240-249
- ISSN
- 0012-6667 (ISSN-L)
- OpenAlex
- W2032185349
- Cited by
- 92
- References
- 50
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 1 · 2020: 2 · 2019: 3 · 2018: 1 · 2016: 2 · 2015: 1 · 2014: 6 · 2013: 1 · 2012: 4
- FWCI
- 5.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Food and Drug Administration (FD-U-000505, FD-R-000179)
- National Center for Research Resources (M-O1-RR-00042, M01RR000042)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Trace Elements in Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Keywords
- Wilson's disease, copper accumulation, copper chelation, zinc therapy, D-penicillamine, triethylenetetramine, tetrathiomolybdate, ceruloplasmin, Kayser-Fleischer rings, underdiagnosis, metallothionein, maintenance therapy
- MeSH terms
- Chelating Agents, Copper, Female, Hepatolenticular Degeneration, Humans, Liver, Metallothionein, Molybdenum, Penicillamine, Pregnancy, Trientine, Zinc
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Practical recommendations and new therapies for Wilson's disease. https://app.cochat.ai/papers/10.2165/00003495-199550020-00004
- The paper
- Brewer, G. J. (1995). Practical recommendations and new therapies for Wilson's disease. Drugs. https://doi.org/10.2165/00003495-199550020-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.